Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population

References

• Lundell K, Wikvall K.Species-specific and age-dependent bile acid composition: Aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr Drug Metab. 2008;9:323–331.
   PubMedGoogle Scholar
• Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, Engström G, Berglund G, Minuz P, Melander O. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008;52:373–380.
   PubMed Web of Science ®Google Scholar
• Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, Liao JK. Activation of G alphas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001, 276:15983–15989.
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation. 2004; 109:178–183.
   PubMed Web of Science ®Google Scholar
• Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163–181.
   PubMed Web of Science ®Google Scholar
• Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol. 2000;27:855–865.
   Google Scholar
• Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;12:12.
   Google Scholar
• Ercan B, Ayaz L, Ciçek D, Tamer L.Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct. 2008;26:309–313.
   Google Scholar
• Imig JD. Epoxygenase metabolites. Epithelial and vascular actions. Mol Biotechnol. 2000;16:233–251.
   PubMed Web of Science ®Google Scholar
• Kinga LM, Gainerb JV, Davida GL, Daia D, Goldsteina JA, Brownb NJ. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenetics Genomics. 2005;15:7–13.
   Google Scholar
• McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol. 1991;31:339–369.
   PubMed Web of Science ®Google Scholar
• Fleming I, Busse R. Vascular cytochrome P450 in the regulation of renal function and vascular tone: EDHF, superoxide anions and blood pressure. Nephrol Dial Transplant. 2001;16: 1309–1311.
   Google Scholar
• Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131–185.
   PubMed Web of Science ®Google Scholar
• Medhora M, Narayanan J, Harder D, Maier KG. Identifying endothelium derived hyperpolarizing factor: Recent approaches to assay the role of epoxyeicosatrienoic acids. Jpn J Pharmacol. 2004;12:369–375.
   Google Scholar
• Gauthier KM, Falck JR, Reddy LM, Campbell WB. 14,15-EET analogs: Characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol Res. 2004;49:515–524.
   Google Scholar
• Sun J, Sui X, Bradbury JA, . Inhibition of vascular smooth muscle cell migration by cytochrome P450 epoxygenase-derived eicosanoids. Circ Res. 2002;90:1020–1027.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, Badr KF. Cytochrome P-450 arachidonate metabolites in rat kidney: Characterization and hemodynamic responses. Am J Physiol. 1990;258:F781–F789.
   PubMed Web of Science ®Google Scholar
• Katoh T, Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, . Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am J Physiol. 1991;261:F578–F586.
   PubMed Web of Science ®Google Scholar
• Yang YN, Wang XL, Ma YT, Xie X, Fu ZY, Li XM, . Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thro-/Hem, 2010, DOI: 10.1177/ 1076029610364522.
   Google Scholar
• Ercan B, Ayaz L, Ciçek D, Tamer L. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct. 2008;26:309–313.
   Google Scholar
• Kitsios GD, Zintzaras E. An NOS3 Haplotype is protective against hypertension in a Caucasian Population. Int J Hypertens. 2010;2010:865031.
   Google Scholar
• Dempster AP, Laird NM, Rubin DB. Maximum likelihood from in complete data via the EM algorithm. J R Stat Soc. 1977;39:1–22.
   Google Scholar
• Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–98.
   PubMed Web of Science ®Google Scholar
• Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, . Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;6:653–658.
   Google Scholar
• Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am Coll Cardiol. 2004;10:1731–1737.
   Google Scholar
• Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;39:36059–36062.
   Google Scholar
• Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys. 2005;2:413–420.
   Google Scholar
• Morris RW, Kaplan NL. On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol. 2002;23:221–233.
   PubMed Web of Science ®Google Scholar
• Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, . Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;11: 992–998.
   Google Scholar